Zydus Lifesciences Limited has informed the Exchange that Board of Directors at its meeting held on May 20, 2025, recommended Final Dividend of Rs. 11.00 per equity share.
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences' Board, at its May 20, 2025 meeting, approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with an unmodified audit opinion from Deloitte Haskins & Sells LLP. Standalone revenue from operations for FY25 rose to Rs. 14,590 crore from Rs. 10,318 crore in FY24, while net profit jumped to Rs. 5,775 crore from Rs. 3,442 crore, with EPS at Rs. 57.39 (vs Rs. 34.01). The Board recommended a final dividend of Rs. 11 per equity share (1100% on face value of Re. 1), subject to shareholder approval at the AGM scheduled for August 12, 2025. Q4 standalone net profit at Rs. 471 crore was lower YoY due to a one-time tax benefit in the base quarter of FY24.
The Rs. 11 dividend marks a sharp increase from the previous year's Rs. 6 final dividend, signaling management's confidence in cash flows and a shareholder-friendly payout. Strong FY25 earnings growth (profit up ~68% YoY standalone) and an unmodified audit opinion are positive signals, though the headline dividend yield works out to roughly 1-1.3% at current market price levels.